You are here:
SKU: 2022-001-1-2-1

DIFF ‘TailorCraft’ Protease Inhibitor Screening System

$1.00

For ‘TalorCraft’ product, please contact us for quotations.

Use of DIFF Biotech products falls under our material transfer agreement and is for non-profit research use only. For commercial use, please contact us for licensing.

Your Customized Solution for Precision Screening

 

Tailored to meet your unique research needs, the DIFF ‘TailorCraft’ Protease Inhibitor Screening System empowers you with a simplified approach to protease inhibitor discovery. With our customizable platform, you can effortlessly provide your specific protease sequences and corresponding cleavage targets. Leveraging advanced technology and expertise, DIFF Biotech swiftly conducts targeted analysis, delivering precise approach to accelerate your research. Say goodbye to one-size-fits-all solutions – with ‘TailorCraft’, experience the power of personalized protease inhibitor screening tailored to your exact specifications. Unlock new possibilities and advance your research with confidence.

Protease inhibitors (PIs) are medications that act by interfering with enzymes that cleave proteins. Widely recognized for their efficacy, they are commonly employed in treating conditions such as HIV/AIDS, hepatitis C, and COVID-19.  Additionally, inhibitors targeting human proteases hold promise in cancer therapy. The traditional strategy to identify and validate new PIs include biochemical and kinetic analysis methods like FRET or using the true virus in cellular level and in vivo animal models. The DIFF assay system offers an innovative ready-to-use screening strategy that combines accuracy with convenience. Researchers can swiftly screen drug candidates at the cellular level without the need for live viruses, expediting the discovery and optimization of PIs.

Throughout years of R&D practice, DIFF BIOTECH has accumulated substantial skills and expertise in screening protease inhibitors as antiviral drugs. The DIFF patented fluorescence reporting assay system eliminates the need to suffer from false-positive results compared to existing screening methods. The fluorescent component is designed to be less costly and the amount and purity of compounds being screened will be lower demand compared to using a FRET screening system. 

Our screening system is based on green fluorescent protein (GFP)-derived protein that fluoresces only after the inhibitor works, and the fluorescence intensity increases with the action of the inhibitor. This experimentally optimized report assay system allows for antiviral drug screening in human cell culture at biosafety level 1 (BSL1) with a high-throughput advantage. Using this screening approach in combination with existing drug libraries may lead to the rapid identification of novel antivirals.

Figure 1: Illustration of the assay principle
Before You Purchase
Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.
An order for materials must have a completed Material Transfer Agreement (MTA) so that the technology can be transferred from one institution to another. The MTA will be sent to you through email after you place an order. We will only ship your order after we received the approved MTA.

You may also like